| CL1948A |
|
356559-13-2 |
SB-505124 HCl
SB-505124 hydrochloride
-
98+%
|
需詢價(jià) |
C20H22ClN3O2 |
|
|
|
| CL1270A |
|
924898-09-9 |
LY2157299 monohydrate
Galunisertib monohydrate | LY2157299 monohydrate
-
98+%
|
需詢價(jià) |
C22H19N5O.H2O |
|
|
|
| CLA1323 |
|
1356922-05-8 |
比瑪盧單抗
Bimagrumab (Anti-ACVR2B)
3-5days
95+%
|
￥3000.00 |
— |
|
|
|
| CLA1157 |
|
705287-60-1 |
司他蘆單抗
Stamulumab (Synonyms: MYO-029)
3-5days
95+%
|
￥9000.00 |
— |
|
|
|
| CLA1151 |
|
272780-74-2 |
美替木單抗
Metelimumab
3-5days
95+%
|
￥3000.00 |
— |
|
|
|
| CLA1141 |
|
948564-73-6 |
非蘇木單抗
Fresolimumab
3-5days
95+%
|
￥6000.00 |
— |
|
|
|
| CL1270 |
|
700874-72-2 |
LY2157299
Galunisertib | LY2157299
3-5days
98+%
|
￥466.00 |
C22H19N5O |
|
|
|
| CL1082 |
|
301836-41-9 |
SB-431542
SB-431542
In-stock
98+%
|
￥350.00 |
C22H16N4O3 |
|
|
|
| CL1542 |
|
1062368-24-4 |
4-[6-(4-(哌嗪-1-基)苯基]吡唑并[1,5-a]嘧啶-3-基)喹啉
LDN-193189(DM3189)
In-stock
98+%
|
￥750.00 |
C25H22N6 |
|
|
|
| CL1057 |
|
1206711-16-1 |
DMH-1
DMH-1 (DMH1)
In-stock
98+%
|
￥400.00 |
C24H20N4O |
|
|
|
| CL1556 |
|
1432597-26-6 |
5-[6-[4-(1-哌嗪基)苯基]吡唑并[1,5-a]嘧啶-3-基]喹啉
LDN-212854 | BMP Inhibitor III | LDN 212854 | 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
-
98+%
|
需詢價(jià) |
C25H22N6 |
|
|
|
| CL1900 |
|
700874-71-1 |
LY2109761
LY2109761
-
98+%
|
需詢價(jià) |
C26H27N5O2 |
|
|
|
| CL1948 |
|
694433-59-5 |
SB-505124
SB-505124
-
98+%
|
需詢價(jià) |
C20H21N3O2 |
|
|
|
| CL1007 |
|
446859-33-2 |
2-[3-(6-甲基-2-吡啶基)-1H-吡唑-4-基]-1,5-萘啶
RepSox (E-616452; SJN 2511;ALK5 Inhibitor II) | 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine
In-stock
98+%
|
￥600.00 |
C17H13N5 |
|
|
|
